CML is characterized by the presence of the Philadelphia chromosome (Ph) and a clonal expansion of neutrophils and their precursors. Ph-positive leukemias have a specific reciprocal translocation, which fuses the ABL proto-oncogene to BCR. BCR/ABL transgenic mice and retroviruses have been used to show that the resulting fusion protein, BCR/ABL, is directly responsible for the generation of leukemia (for review: Baillière's Clin Haematol 10: [187] [188] [189] [190] [191] [192] [193] [194] [195] [196] [197] [198] [199] [200] [201] [202] [203] 1997) . The mechanism(s) by which BCR/ABL causes leukemias is currently the focus of different lines of investigation.
One possible route of aberrant signal transduction involves the phosphorylation of the adaptor protein Crkl. We previously identified this protein as a major in vivo substrate of the deregulated Bcr/Abl tyrosine kinase and established that it functions as a molecular link with other signalling proteins. One of these proteins is p120 Cbl. Interestingly, CBL was isolated in the past as an oncogene associated with myeloid and lymphoid leukemias (Proc Natl Acad Sci USA 1168 -1172 , 1989 .
Very recently, we discovered the identity of a group of prominently tyrosine-phosphorylated proteins with a molecular mass of 110 kDa, which specifically bind to the Crkl SH2 domain in the leukemic tissues of P190 BCR/ABL transgenic mice (J Biol Chem, 272: 32649-32655, 1997) . We demonstrated (see Figure 1 ) that these proteins are identical to Hef1/Cas-L, which is highly similar to p130 Cas. However, unlike p130 Cas, which is ubiquitously expressed, expression of Hef1 is limited to specific cell types within the hematopoietic lineage. Both p120 Cbl and Hef1, but not p130 Cas, were phosphorylated on tyrosine in P190 Bcr/Abl expressing leukemic cells and were in complex with Crkl. We conclude that in this type of leukemia, complexes exist consisting of Bcr/Abl, Crkl, and Hef1 or p120 Cbl. The identification of Hef1 as a substrate for Bcr/Abl and the prior knowledge that Hef1 is involved in ␤ 1 -integrin signalling, indicates a pathway by which Bcr/Abl could interfere with normal ␤ 1 -integrin signalling and might explain the altered adhesion properties of leukemic cells in the bone marrow.
Another important protein in leukemias caused by BCR/ABL is the BCR gene product. Critically, the BCR promoter drives the expression of BCR/ABL and features such as expression pattern and level of expression will have a significant effect on the disease. In addition, several studies have shown that not only the truncated Abl moiety, but also parts of Bcr included within Bcr/Abl contribute to the leukemogenic effect of Bcr/Abl. The 160 kDa BCR gene product has several distinct domains (also see Figure 2 ). The segment encoded by exon 1 has serine/threonine kinase activity in vitro and is responsible for activating ABL in the chimeric BCR/ABL gene product. BCR exons 3-10 have sequence homology to the DBL proto-oncogene, a guanine nucleotide-exchange factor for human CDC42, suggesting a similar catalytic activity for Bcr. This part of BCR is included in the P210 BCR/ABL found in CML, but is absent from the P190. In addition, the carboxy terminal domain of Bcr has a well-described function: it encodes a GTPase activating protein (GAP) for members of the Rho family of G proteins. Although this part is deleted from the Bcr/Abl protein, it is present within the reciprocal translocation gene product: Abl/Bcr. ABL/BCR mRNA was demonstrated to be expressed in leukemic cells and it has been suggested that Abl/Bcr also has a significant role in the disease. Finally, several studies provided evidence that one of the major proteins modified by Bcr/Abl is Bcr itself. Bcr can bind with Bcr/Abl through an oligomerization domain located within the amino terminal domain of Bcr. Bcr/Abl phosphorylates Bcr on tyrosine and it has been proposed that phosphorylation of the endogenous Bcr will contribute to leukemogenesis. Based on its structure and demonstrated functions, Bcr is likely to play a role in signal transduction. However, no naturally occurring mutants have been identified, nor has it directly been shown to participate in signal transduction in vivo. Therefore, we generated bcr null mutant mice to examine the function of Bcr in normal and leukemic cells within the context of a whole organism. We demonstrated that exposure of bcr null mutant mice to Gram-negative endotoxin led to severe septic shock and increased tissue injury by neutrophils. Neutrophils of bcr −/− mice showed a pronounced increase in reactive oxygen metabolite production upon activation, and were more sensitive to priming stimuli. Activated −/− neutrophils displayed an increased p21
Rac2 membrane translocation compared to +/+ neutrophils. These results connect Bcr in vivo with the regulation of Rac-mediated superoxide production by the NADPH-oxidase system of leukocytes and suggest a link between Bcr function and the cell type affected in Ph-positive leukemia (Cell, 719-728, 1995) .
P190 BCR/ABL, bcr −/− mice were generated to explore the effect of the endogenous normal bcr protein on the leukemogenesis caused by Bcr/Abl. However, the incidence, kinetics (Figure 3) , and disease type were very similar in the absence or presence of endogenous bcr protein and did not provide evidence that phosphorylation of endogenous Bcr affects the onset or outcome of Bcr/Abl caused leukemogenesis (Oncogene, 16: 2029 (Oncogene, 16: -2032 (Oncogene, 16: , 1998 .
Several studies provide evidence that specific Bcr domains within Bcr/Abl or Abl/Bcr will contribute to activity of these proteins. The data from the bcr −/− mice demonstrate that the Bcr protein modulates the GTP bound state and thus the subcellular location of p21
Rac2
. The GAP (and possibly the DBL homology) domains may also affect the activity of Rac1 which is closely related to Rac2. Rac1 has been implicated in such processes as the formation of lamellipodia, F-actin uncapping, morphological transformation of platelets and cell cycle progression in response to mitogenic stimulation. Several of these functions could easily be envisioned as contributing to leukemogenesis. Very recently (J Biol Chem 20384-20388, 1997) , we also identified a third Rac homologous gene, RAC3. It will be of significant interest to elucidate the functions of Rac3 in signal transduction and to further define the contribution of specific Bcr domains to the deleterious effects of the BCR/ABL chromosomal translocation product. BCR gene and protein. Translocation breakpoints occur within mbcr (the 71 kb region between exon 1 and exon 2) and will result in a P190 BCR/ABL mRNA, or more commonly within the Mbcr, resulting in the P210 BCR/ABL mRNA. Exon 1 encodes the Bcr domain with an intrinsic serine/threonine kinase activity. DH is the Dbl homology domain of Bcr. This part of the protein has a GDP-GTP exchange factor activity towards members of the rho family. PH is the pleckstrin homology domain. GAP is the GTPase activating protein domain.
Figure 3
Leukemogenesis of P190 BCR/ABL mice within a wildtype (+/+) or bcr null mutant (−/−) genetic background. The curves indicate the percentage survival of P190 BCR/ABL transgenic (TG) mice in a bcr −/− and bcr +/+ background. No significant difference in the mortality rate between the two genotypes was observed.
